AMGN NASDAQ
Amgen Inc.
1W: +4.6%
1M: +7.2%
3M: +13.8%
YTD: +38.5%
1Y: +56.0%
3Y: +73.4%
5Y: +155.8%
$448.10
+3.47 (+0.78%)
Weekly Expected Move ±4.0%
$404
$421
$439
$457
$475
Credit Risk of going bust: lower than 74% of companies Debt: 19.2% of company value Bonds: $1.31B held by 639 funds, 79 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $7.22 (down 98%), Amgen Inc. would be worth roughly what it owes.
Total debt $57.30B against a stock market value of $240.38B.
Distance to default 8.24 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $31.37B (short-term plus half of long-term), stock volatility 29.5%; Altman Z 2.36. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $7.22 (down 98%), Amgen Inc. would be worth roughly what it owes.
Total debt $57.30B against a stock market value of $240.38B.
Distance to default 8.24 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $31.37B (short-term plus half of long-term), stock volatility 29.5%; Altman Z 2.36. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#8
of 19
Drug Manufacturers - General
Technical Signal Map
12 Bullish
1 Neutral
1 Bearish
AMGN
$237B
Amgen Inc.
BULLISH
+66
ABBV
$505B
AbbVie Inc.
BULLISH
+91
PFE
$171B
Pfizer Inc.
BULLISH
+91
SNY
$100B
Sanofi
BULLISH
+84
RHHBF
$393B
Roche Holding AG
BULLISH
+75
NVS
$287B
Novartis AG
BULLISH
+75
LLY
$1.2T
Eli Lilly and Company
BULLISH
+66
GSK
$102B
GSK plc
BULLISH
+59
AZN
$266B
AstraZeneca PLC
BULLISH
+50
GILD
$193B
Gilead Sciences, Inc.
BULLISH
+50
JNJ
$636B
Johnson & Johnson
BULLISH
+43
BMY
$126B
Bristol-Myers Squibb Company
LEAN BULL
+16
NONOF
$172B
Novo Nordisk A/S
NEUTRAL
-2
MRK
$358B
Merck & Co., Inc.
BEARISH
-68
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| AMGN Amgen Inc. | $237B | 27.4 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 56.0 |
| ABBV AbbVie Inc. | $505B | 80.5 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.7 |
| PFE Pfizer Inc. | $171B | 39.3 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.9 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -15.6 |
| RHHBF Roche Holding AG | $393B | 25.8 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 16.8 |
| LLY Eli Lilly and Company | $1.2T | 43.0 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 56.0 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 13.2 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | BULLISH | 3.0 |
| GILD Gilead Sciences, Inc. | $193B | -60.6 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.3 |
| JNJ Johnson & Johnson | $636B | 40.5 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 39.2 |
| BMY Bristol-Myers Squibb Company | $126B | 13.5 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| MRK Merck & Co., Inc. | $358B | 112.0 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 62.7 |
| AMGN Amgen Inc. | $237B | 27.4 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 56.0 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.2 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 19.8 |
| UNH UnitedHealth Group Incorporated | $375B | 23.5 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.7 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 64.8 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -1.8 |
| AMGN Amgen Inc. | $237B | 27.4 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 56.0 |
| ABBV AbbVie Inc. | $505B | 80.5 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.7 |
| PFE Pfizer Inc. | $171B | 39.3 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.9 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -15.6 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.2 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 19.8 |
| RHHBF Roche Holding AG | $393B | 25.8 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 16.8 |
| LLY Eli Lilly and Company | $1.2T | 43.0 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 56.0 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 13.2 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | BULLISH | 3.0 |
| GILD Gilead Sciences, Inc. | $193B | -60.6 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.3 |
| JNJ Johnson & Johnson | $636B | 40.5 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 39.2 |
| UNH UnitedHealth Group Incorporated | $375B | 23.5 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.7 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 64.8 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -1.8 |
| BMY Bristol-Myers Squibb Company | $126B | 13.5 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| MRK Merck & Co., Inc. | $358B | 112.0 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 62.7 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
AMGN vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F